TEL AVIV, Israel, November 13, 2012 /PRNewswire/ --
The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).
The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group. Trendlines Labs is co-located with the Misgav Venture Accelerator - The Trendlines Group's incubator focused exclusively on the development of medtech innovations. Misgav was named "Best Incubator" by Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor in 2010. Trendlines portfolio company Stimatix ( http://www.stimatix-gi.com) was named Israel's best start-up in 2012.
D. Todd Dollinger, Chairman and CEO of Trendlines, stated, "Our work with Endo furthers our market reach and is instrumental to our achieving our mission of creating and developing businesses to improve the human condition."Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, "The Trendlines-Endo agreement is in line with our stated vision of sourcing innovation globally. This partnership complements and bolsters our own internal innovation and product development efforts in the areas of pain and urology. Through this partnership, we are excited to participate in the vibrant medical technology community in Israel. " Endo Health Solutions Inc. ( http://www.endo.com) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. About The Trendlines Group
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV